ALLRAllarity Therapeutics, Inc.

Nasdaq allarity.com


$ 0.50 $ -0.05 (-9.71 %)    

Friday, 07-Jun-2024 15:40:04 EDT
QQQ $ 462.76 $ -0.41 (-0.09 %)
DIA $ 388.38 $ -0.84 (-0.22 %)
SPY $ 533.54 $ -0.65 (-0.12 %)
TLT $ 91.51 $ -1.71 (-1.83 %)
GLD $ 211.60 $ -7.83 (-3.57 %)
$ 0.501
$ 0.53
$ 0.00 x 0
$ 0.00 x 0
$ 0.50 - $ 0.53
$ 0.48 - $ 269.80
2,182,258
na
8.82M
$ 1.32
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-08-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-13-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 10-07-2022 06-30-2022 10-Q
9 05-27-2022 03-31-2022 10-Q
10 05-16-2022 09-30-2021 10-Q
11 05-16-2022 12-31-2021 10-K
12 11-23-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 allarity-therapeutics-reports-clear-clinical-benefits-from-phase-2-trial-improves-cash-balance-of-14m-and-equity-balances-of-15m-withdraws-from-s-1

- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All N...

 why-is-nano-cap-allarity-therapeutics-stock-trading-up-on-thursday

Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jen...

Core News & Articles
Market-Moving News May 2nd
05/02/2024 12:39:37

ALLR: 151% | Allarity Therapeutics shares are trading higher after the company announced that Stenoparib shows a clear clinical...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION